Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy (ORCHARD) - ORCHARD

Study identifier:D6186C00001

ClinicalTrials.gov identifier:NCT03944772

EudraCT identifier:2018-003974-29

CTIS identifier:N/A

Recruiting

Official Title

A biomarker-directed Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer whose Disease Has Progressed on First-Line Osimertinib Therapy.

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Osimertinib, Osimertinib, Osimertinib, Osimertinib, Osimertinib, Osimertinib, Osimertinib, Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Durvalumab, Carboplatin, Carboplatin, Carboplatin, Pemetrexed, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Cisplatin, Datopotamab deruxtecan

Sex

All

Actual enrollment

250

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 25 Jun 2019
Estimated Primary Completion Date: 28 Nov 2025
Estimated Study Completion Date: 28 Nov 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria